SCHEMBL5213193

SCHEMBL5213193

O=C(OCc1ccccc1)[C@H]1CCCNC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.50
F10 P00742 1/20 0.48
SLC6A1 P30531 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
SLC6A11 P48066 1/20 0.47
LMNA P02545 1/20 0.47
SLC6A13 Q9NSD5 1/20 0.47
HTR2C P28335 1/20 0.47
GABRA1 P14867 1/20 0.45
GABRG2 P18507 1/20 0.45
GABRB3 P28472 1/20 0.45
GABRA3 P34903 1/20 0.45
GABRA2 P47869 1/20 0.45
GABRB2 P47870 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
GLA P06280 1/20 0.44
KMT2A Q03164 1/20 0.44
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL611205 1.00 TSHR (0.50) TSHRF10SLC6A1SMN1; SMN2SLC6A11
SCHEMBL5218077 1.00 TSHR (0.50) TSHRF10SLC6A1SMN1; SMN2SLC6A11
Hydrochloric Acid SCHEMBL9084788 0.99 TSHR (0.52) TSHRF10SLC6A1SMN1; SMN2SLC6A11
SCHEMBL10957606 0.96 TSHR (0.49) TSHRF10SMN1; SMN2HTR2CGABRA1
Trifluoroacetic Acid SCHEMBL4705776 0.92 TSHR (0.44) TSHRF10SLC6A1SMN1; SMN2SLC6A11
SCHEMBL15626865 0.91 TSHR (0.52) TSHRSMN1; SMN2HTR2CNPC1RAB9A
SCHEMBL1001991 0.91 TSHR (0.52) TSHRSMN1; SMN2HTR2CNPC1RAB9A
SCHEMBL5222777 0.91 TSHR (0.52) TSHRSMN1; SMN2HTR2CNPC1RAB9A
Hydrochloric Acid SCHEMBL29098520 0.90 TSHR (0.54) TSHRSMN1; SMN2HTR2CNPC1RAB9A
Hydrochloric Acid SCHEMBL1001990 0.90 TSHR (0.54) TSHRSMN1; SMN2HTR2CNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1322596-B1 ZWITTERIONIC TACHYKININ RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2007-08-15 EP disclosed
EP-1322596-A1 ZWITTERIONIC TACHYKININ RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2003-07-02 EP disclosed
US-6479518-B2 PSYCHOLOGICAL DISORDERS MERCK & CO., INC. 2002-11-12 US disclosed
US-20020042431-A1 Zwitterionic tachykinin receptor antagonists MERCK & CO., INC. 2002-04-11 US disclosed
WO-2002024629-A1 ZWITTERIONIC TACHYKININ RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042431-A1 Zwitterionic tachykinin receptor antagonists NPY5R, NPY1R, NPY2R TSHR 241/4885F10 639/4885SLC6A1 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.